Pembrolizumab for Early-Stage Non-Small Cell Lung Cancer
Trial Summary
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on chronic systemic steroid therapy or immunosuppressive therapy, you may need to stop or adjust these medications before participating. It's best to discuss your specific medications with the trial team.
Pembrolizumab has shown promise in treating non-small cell lung cancer (NSCLC) by improving survival rates in patients with advanced stages of the disease, as seen in trials like KEYNOTE-024 and KEYNOTE-010. Additionally, early-phase trials and studies have indicated that pembrolizumab is effective and well-tolerated in various solid tumors, including NSCLC.
12345Pembrolizumab (Keytruda) has been used in various clinical trials and is generally considered safe, but it can cause side effects. Common side effects include fatigue, cough, nausea, and rash, while more serious immune-related side effects like pneumonitis (lung inflammation) can occur in a small percentage of patients.
34567Pembrolizumab is unique because it is an immunotherapy drug that works by blocking a protein called PD-1, which helps the immune system attack cancer cells. Unlike traditional chemotherapy, it is used before surgery to potentially shrink tumors in early-stage non-small cell lung cancer.
23458Eligibility Criteria
Adults over 18 who've had surgery to remove stage I NSCLC with tumors between 1-4 cm and are in good health can join. They must not be pregnant, breastfeeding, or planning to conceive soon. People with certain genetic mutations, previous cancer treatments, active infections like TB or hepatitis, other cancers within the last 3 years, severe allergies to pembrolizumab ingredients, recent live vaccines, autoimmune diseases needing treatment in the past two years or organ transplants cannot participate.Inclusion Criteria
Exclusion Criteria